BCAX vs BDRX

Bicara Therapeutics Inc. vs Biodexa Pharmaceuticals plc — Valuation Comparison 2026

BCAX

Biotechnology
Bicara Therapeutics Inc.
Quality
4.3
out of 10
Value Trap
12
SAFE
Price
$21.75
Last close
Models
7/13
Active
VS

BDRX

Biotechnology
Biodexa Pharmaceuticals plc
Quality
1.7
out of 10
Value Trap
Price
$3.36
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType BCAX Fair ValueBCAX Upside BDRX Fair ValueBDRX Upside
Bayesian DCF Intrinsic $8.47 -61.1% $0.89 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.40 -84.4% $3.04 -7.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCAX vs BDRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCAX vs BDRX — Which Stock Is More Undervalued?

BCAX scores higher with a 4.3/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bicara Therapeutics Inc. (BCAX) and Biodexa Pharmaceuticals plc (BDRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCAX currently trades at $21.75 with a QOC of 4.3/10, while BDRX trades at $3.36 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).